Evidence map›Paper›PMID 41483156›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2026

The role of the TIM-3 receptor in inflammatory bowel disease and autoimmunity: implications for TIM-3 and TCR crosstalk.

M Gabel, A Knauss, M F Neurath, B Weigmann

Abstract readReview
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M GabelDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Kussmaul-Forschungscampus, Hartmannstr. 14, 91054, Erlangen, Germany.
A KnaussDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Kussmaul-Forschungscampus, Hartmannstr. 14, 91054, Erlangen, Germany.
M F NeurathDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Kussmaul-Forschungscampus, Hartmannstr. 14, 91054, Erlangen, Germany.
B WeigmannDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Kussmaul-Forschungscampus, Hartmannstr. 14, 91054, Erlangen, Germany. benno.weigmann@uk-erlangen.de.ORCID http://orcid.org/0000-0002-2398-0844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The T cell immunoglobulin and mucin-domain receptor 3 (TIM-3) is an immune checkpoint receptor with complex effects on T cell activation and tolerance. TIM-3 is expressed on the surface of T cells in close proximity to the T cell receptor (TCR), where it mainly acts co-inhibitory, despite lacking typical inhibitory immunoreceptor inhibition motifs, to regulate T cell activity or apoptosis. However, the underlying molecular mechanisms of its intracellular signal transduction remains incompletely understood. Central for the function of TIM-3 are conserved cytoplasmic tyrosine structures that require phosphorylation for downstream signaling. Previous findings suggest that several kinases linked to TCR signaling, including the Src family kinase Lck and the Tec kinase ITK can interact with TIM-3 and thereby regulate TCR signaling and fine-tune T cell activation and tolerance. The ligand-dependent phosphorylation of TIM-3 by ITK, together with the displacement of the adapter protein Bat3, illustrates how TIM-3 signaling modulates early TCR activation. In this review, we describe the interactions of TIM-3 and its various actors that can trigger TCR signaling. This review also aims to shed light on this complex network by providing an overview of the immune checkpoint receptor TIM-3 and its influence on various autoimmune diseases. The focus here is clearly on inflammatory bowel disease (IBD), and open questions about the TIM-3 network are outlined.

Indexed as

AutoimmunityHepatitis A Virus Cellular Receptor 2Inflammatory Bowel DiseasesReceptors, Antigen, T-CellAnimalsHumansLymphocyte ActivationSignal TransductionT-LymphocytesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Receptors, Antigen, T-CellAutoimmune diseaseInflammationInflammatory bowel diseaseT cell receptorTCR-signalingTIM-3

Identifiers

PMID41483156
PMCPMC12764533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.